lymphocytes Isolated from normal human p i blood thesiz ad export two well-characterized growth factors, rin-bindig epdermal growth factor-like growth factor (HB-EGF) and bas fibroast growth factor (bFGF). This consion ls based on mRNA eo analysis, heparinaffinity chromatography profiles, target-cell sificity, and functiona Inhibition by spcific tr a . Atypically, a substantial amount of T-ce-derived bFGF-lke activity appears to be constitutively releaedi into d o medium, almost as much as is aocitd with T-cell lysates. bFGF is synthesized and exported by puri CD4+ and CDS+ T cells, whereas HGB-EGF is and exorted pr y by CD4+ T cells. The T-cell-derlved HB-EGF and bFGF activities are potent maitoens for flass and smooth muscle cells, and the bFGF-like activity is also mt ic for e a cells. These esilts suggest that T lymphocytes may play key roles in meti soth muscle hyp scited with atherosand Ill _-a td with wound healing and tumor growth by acting locally to deliver vascular-cell growth factors to tissues.
T lymphocytes are a major cellular component ofthe immune system whose normal physiological functions include defense against infectious organisms, immune surveillance against cancer, and promotion of wound healing. They are classified into two main subsets, CD4+ and CD8+ cells. CD4+
T cells are known as helper cells because they aid in the induction and maintenance of an immune response by producing cytokines such as interleukin 2 (IL-2), interferon y, tumor necrosis factor a, and granulocyte/macrophagecolony-stimulating factor in response to the recognition of antigenic peptides (1) (2) (3) (4) . CD8+ T cells are known as cytotoxic T lymphocytes because their primary function is the destruction of infected or transformed cells by means of recognition of antigenic peptides presented by class I major histocompatibility molecules (3) .
T cells infiltrate wounds, tumors, and atherosclerotic plaques, processes characterized by the migration and proliferation of vascular endothelial cells (ECs) (angiogenesis), vascular smooth muscle cells (SMCs), and fibroblasts. For example, in atherogenesis characterized by SMC hyperplasia and the vascularization offibrous plaques, numerous activated T cells together with lipid-laden macrophages and SMCs are present in fatty streaks, advanced fibrous lesions, and atherosclerotic plaques (5) . Angiogenesis, SMC hyperplasia, and formation of granulation tissue in wounds are mediated by specific growth factors that stimulate the migraton and proliferation of vascular cells and fibroblasts. Some of the best characterized of these chemotactic and mitogenic factors are platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), transforming growth factor a (TGF-a), and heparin-binding epidermal growth factor-like growth factor (HB-EGF). These growth factors have been shown to be produced by monocytes and macrophages, cells thought to play an important role in angiogenesis, wound healing, and pathological processes such as atherosclerosis (5) . However, while T lymphocytes are usually found at the same sites as monocytes/macrophages in wounds, atherosclerotic plaques, and tumors, there has been no clear demonstration that T lymphocytes produce growth factors that directly stimulate vascular cell and fibroblast proliferation.
In this report, we demonstrate that T lymphocytes synthesize and export at least two heparin-binding vascular cell/fibroblast growth factors, HB-EGF and basic FGF (bFGF). HB-EGF, a 22-kDa heparin-binding growth factor which is a structurally homologous member of the EGF family, was first identified in macrophage conditioned medium (CM) and is a potent mitogen and chemotactic factor for SMCs and fibroblasts, but not for ECs (6) . HB-EGF is a far more potent growth factor for SMCs than are EGF and TGF-a due to its ability to bind to SMC surface heparan sulfate proteoglycan which in turn facilitates its binding to the EGF receptor (7) . It has been suggested that HB-EGF plays a role in vivo in promoting wound healing (8) and the SMC hyperplasia associated with pulmonary hypertension (9) .
bFGF is a potent 18-kDa heparin-binding mitogen for fibroblasts, SMCs, and ECs, as well as an angiogenesis factor (reviewed in refs. 10 and 11 proliferation that occurs following intra-arterial injury (12 with fluorescein-and phycoerythrin-conjugated mAbs (20 A4) directed against CD3, CD4, and CD8 (Becton Dickinson) and using two-color analysis on a Coulter EPICS C cytometer.
Heparin-Affinity Chromatography. T lymphocytes (5 x 107) were cultured for 4 days at 106 cells per ml in fresh complete lymphocyte medium with IL-2 (50 units/ml). Earlypassage (passages 3-4) bovine aortic SMCs were cultured for 3 days in 75-cm2 flasks (2-5 x 106 cells when confluent) in Dulbecco's modified Eagle's medium (DMEM) (GIBCO) supplemented with 10o fetal bovine serum and antibiotics (6) . CM was collected from both cell types and the cells were lysed with 10 mM Tris-HCl, pH 7.2/0.2 M NaCl/30 mM octyl glucoside/10 mM benzamidine/1 mM EDTA/1 mM aprotinin (Boehringer Mannheim)/1 mM leupeptin (Sigma). For heparin-affinity chromatography, samples were analyzed first on heparin-Sepharose minicolumns (Pharmacia) by batch elution with 2 M NaCl and then by FPLC (Pharmacia) using a heparin-TSK 5PW column (6) .
Mitogenic Assays. DNA synthesis in monolayers ofBALB/c 3T3 mouse fibroblasts, bovine ECs, and bovine SMCs was measured as described (6) . To measure stimulation of EP-170 cells expressing EGF receptor (14) and F32 cells expressing FGF receptor (15) (17) , and human prostate adenocarcinoma PC3 cells (18) was isolated by a rapid guanidinium thiocyanate procedure (19) . RNA gel electrophoresis and Northern hybridization were performed as described (20) . The bFGF probe was a 1.4-kb EcoRI cDNA fiagment containing the complete human bFGF coding region (21) . The HB-EGF probe was a 1.1-kb EcoRI cDNA fragment containing the complete coding region of the human HB-EGF (6). The amphiregulin probe was a 0.9-kb EcoRI-HindIll cDNA fragment containing the coding region ofhuman amphiregulin (22) . Double-stranded cDNA probes were labeled to high specific activity (4109 cpm/pg) with 32Pby the random oligonucleotide method (Multiprime labeling kit, Amersham). For Northern analysis, denatured probe (106 cpm/ml) was added to the hybridization bags along with 500 ,g of sheared salmon DNA.
Autoradiography was performed for required times by exposure ofmembranes to x-ray film. Densitometric quantitation of the autoradiographic signal was performed with a PhosphorImager (Molecular Dynamics).
RESULTS
Production and Release ofHB-EGF and bFGF-Like Activities by T Lymphocytes. To ascertain whether T cells secrete heparin-binding vascular-cell growth factors, 3-week-cultured human periperal blood lymphocytes were incubated in fresh complete lymphocyte medium for 4 days and the CM was analyzed by heparin-affinity chromatography (Fig. 1) . Unconditioned medium contained two peaks ofgrowth factor activity for 3T3 cells, eluted with 0.3 and 0.5 M NaCl from heparin-TSK columns (Fig. 1A) . By 2-3 days these peaks of mitogenic activity had disappeared and two new 3T3 mitogenic activities eluted with 1.0-1.2 M NaCl (peak 1) and 1.6-1.9 M NaCl (peak 2) were observed that persisted for at least 7 days. The heparin-affinity profile of T-cell medium conditioned for 4 days is shown in Fig. 1B . These heparin-binding growth factor activities were found not to be processed from heparin-binding growth factors already present in the serum component of the medium (data not shown).
The growth factor activity in peak 1 was shown to be related to HB-EGF. As is the case with HB-EGF (23), the mitogenic activity in peak 1 was resistant to exposure to pH 2.5 for 1 hr and to 900C for 5 min but was totally inactivated after incubation with 5 mM dithiothreitol for 1 hr. Furthermore, the peak 1 growth factor activity comigrated on heparin-TSK columns with human recombinant HB-EGF (Fig. 1B, open arrow) and stimulated the proliferation of 3T3 cells (Fig. 1B) and SMCs (Fig. 1C) , but not ECs (Fig. iD) , thus showing target-cell specificity characteristic ofHB-EGF (11) . Peak 1 growth factor activity was EGF-like in that it stimulated the proliferation of EP-170 cells (Fig. lE) , which are 32D myeloid cells transfected with the EGF receptor and as a result are uniquely responsive to EGF-like growth factors in the absence of IL-3 (14) . Parental 32D cells (data not shown) and lymphoid cells transfected with FGF receptor (Fig. iF) were not stimulated. Amphiregulin, a heparin-binding growth factor structurally related to HB-EGF (6, 13), was not a SMC mitogen (data not shown) and was a relatively poor mitogen for 3T3 cells (data not shown; ref. 13 ) and therefore could not be responsible for the peak 1 mitogenic activity shown in Fig. 1 B and C. An anti-HB-EGF neutralizing antibody which inhibited purified U-937 cell-derived HB-EGF growth factor activity for 3T3 cells by >80% also neutralized peak 1 mitogenic activity to the same degree (data not shown). This antibody did not inhibit amphiregulin or the growth factor activity in peak 2. On the other hand, the growth factor activity in peak 2 was shown to be related to bFGF (Fig. 1) . It was acid-and heat-sensitive but dithiothreitol-resistant, characteristic of bFGF. It comigrated with recombinant human bFGF (Fig.  1B, filled arrow) and stimulated 3T3 cell (Fig. 1B) , SMC (Fig.  1C) , and EC (Fig. 1D ) proliferation, consistent with known target-cell specificities of bFGF. Peak 2 activity also had the properties of a FGF-like growth factor since it stimulated in a heparin-dependent manner the proliferation of F32 cells (Fig. 1F) . These are BaF3 lymphoid cells transfected with the FGF receptor cloneflg and uniquely responsive to FGF-like growth factors in the absence ofIL-3, but only in the presence of exogenous heparin (15) . Parental BaF3 cells (data not shown) and EP-170 cells (Fig. 1E) were not stimulated. Anti-bFGF neutralizing antibodies which inhibited recombinant bFGF activity by 80%6 inhibited the 3T3 cell mitogenic activity of the peak 2 factor by about 70% (data not shown). This antibody had no effect on peak 1 growth factor activity.
T-CeD HIB-EGF and bFGF mRNA Levels. In addition to producing and exporting HB-EGF-and bFGF-like growth factor activities, T lymphocytes contained HB-EGF and bFGF mRNA (Fig. 2) lized heparin with 1.6-1.8 M NaCl was found in SMC lysate; (Fig. 3A) but not in CM (Fig. 3B) . This activity peak stimulated F32 cell proliferation in the presence ofheparin and was neutralized by anti-bFGF antibodies (data not shown). On the other hand, T lymphocytes, cultured for 4 days and 97% viable as ascertained by trypan blue exclusion, exported substantial bFGF-like (peak 2) activity (Fig. 3D) , about 65% as much as was found in T-cell lysates (Fig. 3C) . In three separate experiments, the amount of bFGF released by T cells was 65-95% relative to cell-associated bFGF. These results suggest that T cells might have an atypical mechanism for bFGF release. Bioactive HB-EGF was found in T-cell CM (Fig. 3D) but not in cell lysates (Fig. 3C) . The possibility that there is also cell-associated HB-EGF cannot be ruled out since HB-EGF is produced as a membrane-anchored precursor (6) . However, the mitogenic activity of this membraneanchored and hence insoluble form of HB-EGF is difficult to quantitate.
Differential Release of BB-EGF by CD4+ and CD8+ Lymphocytes. CD4+ (helper) and CD8+ (cytotoxic) T cells differ in their function as well as their cytokine production profile (3). Accordingly, mixed peripheral blood lymphocytes were separated into CD4+ (helper) and CD8+ (cytotoxic) T-cell populations that were >92% pure as ascertained by immunofluorescent staining and flow cytometry (Fig. 4A) . As was the case for mixed T cells, purified CD4+ T cells cultured for 4 days were found to release mitogens that were eluted at 1.0-1.2 M and 1.6-1.9 M NaCl (Fig. 4B Left) . These peaks were confirmed by target-cell specificity and immunoneutralization studies to be HB-EGF-and bFGF-like respectively. In contrast, CD8+ cells released the bFGF-like growth factor, but no HB-EGF-like activity was detectable (Fig. 4B  Right) .
Besides being secreted, HB-EGF is also found associated with cells as a membrane-bound precursor (7) and could be synthesized by CD8+ T cells but not be exported. However, Northern blot analysis (Fig. 5) size, at the mRNA and protein levels, HB-EGF-and bFGFlike molecules that are direct mitogens for vascular cells and fibroblasts. T-lymphocyte-derived HB-EGF stimulates fibroblast and SMC proliferation, whereas T-lymphocyte-derived bFGF stimulates the proliferation of these two cell types and ECs as well. Interestingly, T cells do not seem to produce amphiregulin, an EGF-like growth factor with about 40% sequence homology to HB-EGF (6, 13) .6% 0 heparin-binding properties. Nor do they produce detectable levels of PDGF, a potent SMC mitogen, in that heparinaffinity chromatography of T-cell CM did not reveal any PDGF-like peaks of activity eluted at 0.5-0.6 M NaCi. Thus, there is a degree of specificity in the production of vascularcell growth factors by T cells.
Surprisingly, the induction of HB-EGF and bFGF in culture does not require anyT-cell receptor/CD3 complexmediated stimuli. Rather, the depletion of the serumsupplemented medium by these cells is sufficient. These results suggest that T lymphocytes may be stimulated in vivo to produce HB-EGF and bFGF when exposed to an environment such as the hypoxic and/or ischemic conditions associated with tissue injury. The need for exposure to culture conditions might explain why no bFGF was detected in fresh human peripheral blood T lymphocytes in the absence of cell culture (24) .
Another potentially significant result is the finding that CD4+ and CD8+ T cells have different profiles of HB-EGFand bFGF-like export. While bFGF is synthesized and exported by both purified CD4+ and purified CD8+ T cells, HB-EGF is synthesized and exported primarily by CD4+ T cells. It is possible that CD4+ T cells, the subset most active in secreting cytokines, might be best suited for HB-EGF production.
An additional finding is that fillly viable T lymphocytes export substantial bFGF-like activity. The 4-day CM has almost as much bFGF-like activity as remains associated with the T-cell lysate. Under the same experimental conditions, SMCs release no detectable bFGF, consistent with the lack of a bFGF secretion signal peptide (21) . There has been areport ofbFGF export by fibrosarcoma cells but not by their normal counterparts (25) . One possibility is that T cells, by some yet undetermined mechanism, export authentic bFGF. There have been several reports of proteins lacking a signal peptide being exported-e.g., IL-, the lectin L14, and acidic FGF (aFGF) (26) (27) (28) . Alternatively, the T-cell-derived bFGF may be a homologous gene product that has obtained a signal peptide by alternative splicing or a form of bFGF that has been posttranslationally modified to facilitate export. There are six other known members of the FGF family, which, unlike authentic aFGF and bFGF, do possess signal peptides and are exported (11, 29) . However, none of these FGF homologues match T-lymphocyte-derived bFGF in terms of heparin-affinity elution profiles, target-cell specificity, hepann requirements for mitogenicity, and neutralization by anti-bFGF antibodies.
The biological significance of this study is the possible direct connection we'can now make between the lymphocyte component of the immune system and the migration and proliferation of vascular cells and fibroblasts. T lymphocytes are known to play a significant role in such diverse biologic processes as wound healing, autoimmune disease, allograft rejection, atherosclerosis, and cancer, processes in which mesenchymal cells migrate and proliferate. Analysis of mesenchymal-cell growth factors in the immune/inflammatory defense response has focused mostly on macrophages, even though T lymphocytes infiltrate many of the same tissues. The role ofbFGF in stimulating wound and tumor angiogenesis, granulation tissue, and SMC hyperplasia is well documented (10, 12) . More recently, HB-EGF has been shown to be associated with wound healing (8) and pulmonary hypertension (9) . Our preliminary experiments indicate that infiltrating lymphocytes obtained from multiple cancers and atherosclerotic plaques produce HB-EGF and bFGF (unpublished work). Our goal is to determine whether HB-EGF and bFGF delivered by infiltrating T lymphocytes mediate normal growth, as occurs in wound healing, and pathological growth as occurs in the SMC hyperplasia associated with atherosclerosis, fibrosis associated with autoimmune disease, and angiogenesis associated with tumors.
